News|Articles|April 8, 2025

Q1 Sleep Medicine Updates

Q1 2025 sleep updates include FDA rejecting pitolisant NDA for idiopathic hypersomnia, iptacopan improving PNH fatigue, and more.

In the first quarter of 2025, sleep medicine saw a mix of regulatory shifts and promising clinical data. Although the US Food and Drug Administration (FDA) rejected the New Drug Application (NDA) for pitolisant in idiopathic hypersomnia, plans for a new registrational trial are underway.